Acute Heart Failure - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Acute Heart Failure - Pipeline Review, H1 2015', provides an overview of the Acute Heart Failure's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Acute Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Heart Failure and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Heart Failure - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acute Heart Failure and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Acute Heart Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Acute Heart Failure pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute Heart Failure - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute Heart Failure pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Acute Heart Failure Overview 7 Therapeutics Development 8 Pipeline Products for Acute Heart Failure - Overview 8 Pipeline Products for Acute Heart Failure - Comparative Analysis 9 Acute Heart Failure - Therapeutics under Development by Companies 10 Acute Heart Failure - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Acute Heart Failure - Products under Development by Companies 15 Acute Heart Failure - Companies Involved in Therapeutics Development 16 Amgen Inc. 16 Anexon, Inc. 17 Angion Biomedica Corp. 18 Bayer AG 19 Lee's Pharmaceutical Holdings Limited 20 Novartis AG 21 Nyken BV 22 Ono Pharmaceutical Co., Ltd. 23 PhaseBio Pharmaceuticals, Inc. 24 Trevena, Inc. 25 Acute Heart Failure - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 ANG-4011 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 ANX-042 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 BR-5489 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 cenderitide - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 istaroxime - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 NYK-1112 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 omecamtiv mecarbil - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 ONO-4232 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 PB-1046 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 serelaxin - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 TRV-027 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 TRV-120023 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 ularitide - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Acute Heart Failure - Recent Pipeline Updates 56 Acute Heart Failure - Dormant Projects 68 Acute Heart Failure - Discontinued Products 69 Acute Heart Failure - Product Development Milestones 70 Featured News & Press Releases 70 Oct 16, 2014: Cardiorentis AG and Roche Announce Collaboration to Establish Therapeutic Impact of Ularitide 70 Oct 09, 2014: Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation 70 Aug 05, 2014: Trevena Granted Key U.S. Method of Use Patent for TRV027 71 May 23, 2014: Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure 72 May 19, 2014: Trevena Highlights Phase 2b-BLAST AHF Trial for TRV027 at the European Society of Cardiology Heart Failure 2014 Meeting 72 May 16, 2014: FDA issues Complete Response Letter for RLX030 for acute heart failure 73 Mar 27, 2014: Novartis to work with FDA on path forward for RLX030 for acute heart failure following Advisory Committee outcome 74 Mar 25, 2014: FDA Staff Says Novartis' Serelaxin Shouldn't Be Approved 74 Jan 24, 2014: Novartis Europharm's Reasanz Receives CHMP Negative Opinion 75 Jan 24, 2014: Novartis to request re-examination of serelaxin in acute heart failure for conditional marketing authorization in EU 76 Appendix 77 Methodology 77 Coverage 77 Secondary Research 77 Primary Research 77 Expert Panel Validation 77 Contact Us 78 Disclaimer 78
List of Tables Number of Products under Development for Acute Heart Failure, H1 2015 8 Number of Products under Development for Acute Heart Failure - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 11 Comparative Analysis by Late Stage Development, H1 2015 12 Comparative Analysis by Clinical Stage Development, H1 2015 13 Comparative Analysis by Early Stage Development, H1 2015 14 Products under Development by Companies, H1 2015 15 Acute Heart Failure - Pipeline by Amgen Inc., H1 2015 16 Acute Heart Failure - Pipeline by Anexon, Inc., H1 2015 17 Acute Heart Failure - Pipeline by Angion Biomedica Corp., H1 2015 18 Acute Heart Failure - Pipeline by Bayer AG, H1 2015 19 Acute Heart Failure - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 20 Acute Heart Failure - Pipeline by Novartis AG, H1 2015 21 Acute Heart Failure - Pipeline by Nyken BV, H1 2015 22 Acute Heart Failure - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 23 Acute Heart Failure - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2015 24 Acute Heart Failure - Pipeline by Trevena, Inc., H1 2015 25 Assessment by Monotherapy Products, H1 2015 26 Number of Products by Stage and Target, H1 2015 28 Number of Products by Stage and Mechanism of Action, H1 2015 30 Number of Products by Stage and Route of Administration, H1 2015 32 Number of Products by Stage and Molecule Type, H1 2015 34 Acute Heart Failure Therapeutics - Recent Pipeline Updates, H1 2015 56 Acute Heart Failure - Dormant Projects, H1 2015 68 Acute Heart Failure - Discontinued Products, H1 2015 69
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.